Sana Biotechnology

### Executive Summary Sana Biotechnology raised $924.2M in a Regulation D private placement, first sale on 2025-10-12, indicating massive institutional confidence in synthetic biology and intracellular mRNA delivery. The involvement of Andreessen Horowitz and Sands Capital as related persons signals deep-pocketed backers, though this is a private offering, not a public IPO. ### Investor Edge Watch for an eventual D/A amendment (Form D/A) which would indicate additional capital or changed terms, and monitor for any public filing (e.g., S-1) that could signal a future IPO or reverse merger, given the size of this raise. ### Sector capital positioning This $924.2M raise is one of the largest private capital infusions in synthetic biology, signaling a strong capital flow into intracellular mRNA delivery platforms and potentially accelerating convergence with gene editing and cell therapy. ### Convergence Signals No direct public signals (patents, contracts, legislation) are evident from the filing data. However, the massive raise suggests upcoming clinical or manufacturing milestones that could impact public biotech indices or competitors. ### Key Takeaways - Sana Biotechnology raised $924.2M in a private placement, one of the largest in synthetic biology. - Andreessen Horowitz and Sands Capital are listed as related persons, indicating top-tier investor involvement. - No public ticker yet; this is a private company with a Regulation D filing. ### Risk Indicators & Flags No D/A amendments yet (this is an initial Form D). The sector (synthetic biology & intracellular mRNA delivery) is high-risk/high-reward, with regulatory and clinical trial risks. The massive amount ($924.2M) for a private company may signal aggressive burn rate or pre-IPO positioning. ### Verification & References Filing is Form D (initial notice) with SEC accession 0001702600-24-20383, first sale date 2025-10-12, capital raised $924.2M. Verify at SEC EDGAR using company name 'Sana Biotechnology' and form type D. Related persons include Andreessen Horowitz and Sands Capital as officers/directors, not necessarily capital sources.